Sanofi SA SAN

The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.

Sanofi and Regeneron are broadening their immunology pipeline while keeping their existing Dupixent economics intact.

Investing.com -- Shares of Sanofi jumped as much as 3.6% on Thursday before paring gains to trade 1.1% higher after the French drugmaker agreed to pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four long-acting medicines for inflammatory diseases.

Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from RegeneronRegeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share dev

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Regeneron and Sanofi to host a conference

The liquidation auctioneer Liquidity Services is closing in on a buy point. The stock is up roughly 45% this year.

Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capacity, with the goal of strengthening readiness for future influenza seasons. Sanofi agreed to transfer a portfolio of mature medicines and several manufacturing sites to Cheplapharm, while also taking an equity stake in the partner. The inauguration of the Charles Best Building and the broadened...

European equities traded in the US as American depositary receipts were tracking lower Wednesday mor

All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.